BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1891175)

  • 1. Serum sialyl-Tn antigen levels in patients with digestive cancers.
    Motoo Y; Kawakami H; Watanabe H; Satomura Y; Ohta H; Okai T; Makino H; Toya D; Sawabu N
    Oncology; 1991; 48(4):321-6. PubMed ID: 1891175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas.
    Nanashima A; Yamaguchi H; Nakagoe T; Matsuo S; Sumida Y; Tsuji T; Sawai T; Yamaguchi E; Yasutake T; Ayabe H
    J Hepatobiliary Pancreat Surg; 1999; 6(4):391-5. PubMed ID: 10664288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients.
    Takahashi I; Maehara Y; Kusumoto T; Kohnoe S; Kakeji Y; Baba H; Sugimachi K
    Br J Cancer; 1994 Jan; 69(1):163-6. PubMed ID: 8286201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
    Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
    Olsson NO; Crimet-Montange D; Martin F
    Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of tumor-associated glycoprotein (TAG-72) in digestive cancers.
    Motoo Y; Satomura Y; Kawakami H; Watanabe H; Ohta H; Okai T; Sawabu N
    Oncology; 1990; 47(6):456-62. PubMed ID: 2243663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
    Kuusela P; Haglund C; Roberts PJ
    Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating sialyl Lewis(x), sialyl Lewis(a), and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels.
    Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Kurosaki N; Yasutake T; Ayabe H
    J Gastroenterol; 2001 Mar; 36(3):166-72. PubMed ID: 11291879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
    Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
    Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.
    Haglund C; Roberts PJ; Jalanko H; Kuusela P
    Scand J Gastroenterol; 1992; 27(3):169-74. PubMed ID: 1502477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
    Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
    Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.
    Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M
    Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer.
    Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K; Ishikawa H
    Eur J Surg Oncol; 2001 Dec; 27(8):731-9. PubMed ID: 11735169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
    Kobayashi H; Terao T; Kawashima Y
    J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers.
    Arakawa Y; Ariga H; Kano M; Matsuo Y; Honda T; Morita K
    Jpn J Med; 1985 May; 24(2):121-30. PubMed ID: 3860677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer.
    Kobayashi H; Terao T; Kawashima Y
    J Clin Oncol; 1992 Jan; 10(1):95-101. PubMed ID: 1727929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
    Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
    J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour marker CA 125 in patients with digestive tract malignancies.
    Haglund C; Kuusela P; Roberts P; Jalanko H
    Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CA 19-9 in neoplasms. Comparison with CEA].
    Nakad A; Jonard P; Geubel A; Warzee P; Coppens JP; Dehennin JP; Dive C
    Acta Gastroenterol Belg; 1987; 50(1):36-44. PubMed ID: 3480669
    [No Abstract]   [Full Text] [Related]  

  • 20. [Serum determination of CA 19-9 in patients with digestive cancers and its diagnostic evaluation].
    Arakawa Y; Kobayashi H; Ozaki T; Ariga H; Matsuo Y; Honda T; Arai T; Kurosu Y; Morita K; Konuma H
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):917-25. PubMed ID: 6586110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.